Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,981 to 4,000 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Total Knee Replacement vs Total Hip Replacement: Prescription for Nursing Care and Nurse Visits on the Day of Hospital Discharge | 420 of 746 584 of 929 | -6.6 points -11.3 to -1.8 | 1,675 | NCT01139658 Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA |
| Total Knee Replacement vs Total Hip Replacement: Occurrence of Major Bleeding Events | 8 of 746 16 of 929 | -0.6 points -1.8 to 0.6 | 1,675 | NCT01139658 Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA |
| Total Knee Replacement vs Total Hip Replacement: Number of Patients Who Switched to Another Anticoagulant Therapy | 43 of 746 45 of 929 | 0.9 points -1.2 to 3.2 | 1,675 | NCT01139658 Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA |
| Total Knee Replacement vs Total Hip Replacement: Prescription for the Surveillance of the Platelet Count on the Day of Hospital Discharge | 24 of 746 44 of 929 | -1.5 points -3.4 to 0.4 | 1,675 | NCT01139658 Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA |
| Total Knee Replacement vs Total Hip Replacement: Occurrence of Symptomatic Venous Thromboembolic Events | 19 of 746 5 of 929 | 2.0 points 0.9 to 3.4 | 1,675 | NCT01139658 Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA |
| Total Knee Replacement vs Total Hip Replacement: serious adverse events | 48 of 746 37 of 929 | 2.5 points 0.3 to 4.7 | 1,675 | NCT01139658 Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA |
| SOC Arm vs Enhanced Arm: Number of Participants Accessing Sexual and Reproductive Health Related Prevention Services Within 12 Months | 214 of 816 297 of 859 | -8.3 points -12.7 to -3.9 | 1,675 | NCT04429061 Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ |
| Generic Best Practices (GBP) vs Tailored Best Practices (TBP): Full COVID-19 Vaccination Status Among Staff | 467 of 836 471 of 837 | -0.4 points -5.2 to 4.3 | 1,673 | NCT04726371 Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings |
| Fast-tracked vs Control: Daily Service Denials (Bumps) | 0 of 111 29 of 1,561 | -1.9 points -2.7 to 1.5 | 1,672 | NCT01639443 Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy |
| Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Mortality | 50 of 846 54 of 826 | -0.6 points -3.0 to 1.7 | 1,672 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Percentage Seizure-free for 6 Months, or Longer, Measured at 24 Months After Enrollment | 371 of 846 299 of 826 | 7.7 points 3.0 to 12.3 | 1,672 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| Task-shifted Arm vs Enhanced Usual Care Arm: Anytime 6-month Seizure-free Interval | 448 of 846 440 of 826 | -0.3 points -5.1 to 4.5 | 1,672 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): deaths from any cause | 50 of 846 54 of 826 | -0.6 points -3.0 to 1.7 | 1,672 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): serious adverse events | 33 of 846 25 of 826 | 0.9 points -0.9 to 2.7 | 1,672 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| PLWHIV and Mpox Coinfection vs HIV Negative PrEP Users With Mpox Infection: Severe Mpox Lesions | 6 of 766 2 of 906 | 0.6 points -0.2 to 1.5 | 1,672 | NCT05965427 Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV |
| Drotrecogin Alfa (Activated) vs Placebo: serious adverse events | 119 of 833 96 of 833 | 2.8 points -0.5 to 6.0 | 1,666 | NCT00604214 Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock |
| Arm 1 (Control) vs Arm 2 (Consumer-directed and Provider-directed Intervention): ACT (Artemisinin Combination Therapy) Use Among Untested Participants | 462 of 836 498 of 827 | -5.0 points -9.7 to -0.2 | 1,663 | NCT04428385 Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria |
| Medtronic CoreValve® System TAVI vs SAVR: deaths from any cause | 98 of 864 80 of 796 | 1.3 points -1.7 to 4.3 | 1,660 | NCT01586910 Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). |
| Medtronic CoreValve® System TAVI vs SAVR: serious adverse events | 718 of 864 694 of 796 | -4.1 points -7.5 to -0.7 | 1,660 | NCT01586910 Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). |
| Sulopenem-etzadroxil/Probenecid vs Ciprofloxacin: deaths from any cause | 1 of 833 0 of 827 | 0.1 points -0.4 to 0.7 | 1,660 | NCT03354598 Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women |
Code
curl "https://conductscience.org/api/comparisons/v1?page=200"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=200
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01139658-3c9ded75",
"title": "Total Knee Replacement vs Total Hip Replacement: Prescription for Nursing Care and Nurse Visits on the Day of Hospital Discharge",
"summary": "420 of 746 against 584 of 929; risk difference -6.6 points, 95% interval -11.3 to -1.8; NCT01139658, Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA",
"record": "/library/comparisons/NCT01139658-3c9ded75",
"nct_id": "NCT01139658",
"kind": "outcome",
"participants": 1675,
"risk_difference": {
"value": -0.06563025767855546,
"lower": -0.11266878747343745,
"upper": -0.018381001566961937
},
"group_1": "420 of 746",
"group_2": "584 of 929",
"difference": "-6.6 points",
"interval": "-11.3 to -1.8",
"trial_title": "Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA"
},
{
"id": "NCT01139658-45ea09d5",
"title": "Total Knee Replacement vs Total Hip Replacement: Occurrence of Major Bleeding Events",
"summary": "8 of 746 against 16 of 929; risk difference -0.6 points, 95% interval -1.8 to 0.6; NCT01139658, Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA",
"record": "/library/comparisons/NCT01139658-45ea09d5",
"nct_id": "NCT01139658",
"kind": "outcome",
"participants": 1675,
"risk_difference": {
"value": -0.006498959647001444,
"lower": -0.01831468389796357,
"upper": 0.005725361529793914
},
"group_1": "8 of 746",
"group_2": "16 of 929",
"difference": "-0.6 points",
"interval": "-1.8 to 0.6",
"trial_title": "Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=201",
"request_id": "SggUekqBE9dTTXiq"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant